Evidence map›Paper›PMID 34638446›Full record

ArticleCancers2021

Early Changes in DCE-MRI Biomarkers May Predict Survival Outcomes in Patients with Advanced Hepatocellular Carcinoma after Sorafenib Failure: Two Prospective Phase II Trials.

Bang-Bin Chen, Zhong-Zhe Lin, Yu-Yun Shao, Chiun Hsu, Chih-Hung Hsu, Ann-Lii Cheng, Po-Chin Liang, Tiffany Ting-Fang Shih

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Bang-Bin ChenDepartment of Medical Imaging, National Taiwan University Hospital, Taipei City 100, Taiwan.ORCID 0000-0001-7058-1427
Zhong-Zhe LinDepartment of Oncology, National Taiwan University Hospital, Taipei City 100, Taiwan.
Yu-Yun ShaoDepartment of Oncology, National Taiwan University Hospital, Taipei City 100, Taiwan.ORCID 0000-0001-7334-1912
Chiun HsuDepartment of Oncology, National Taiwan University Hospital, Taipei City 100, Taiwan.
Chih-Hung HsuDepartment of Oncology, National Taiwan University Hospital, Taipei City 100, Taiwan.
Ann-Lii ChengDepartment of Oncology, National Taiwan University Hospital, Taipei City 100, Taiwan.
Po-Chin LiangDepartment of Medical Imaging, National Taiwan University Hospital, Taipei City 100, Taiwan.
Tiffany Ting-Fang ShihDepartment of Medical Imaging, National Taiwan University Hospital, Taipei City 100, Taiwan.
National Taiwan University · TW

Funding

Ministry of Science and Technology NSC-100-2314-B-002-053, NSC 102-2321-B-002 -008, MOST 103-2321-B-002 -084, MOST 104-2321-B-002-030, and MOST 110-2314-B-002-144National Taiwan University Hospital NTUH 101-001863, NTUH 104-S2723, NTUH 105-S3096, FN-104002, NTUH 110-S4869
6 · The paper itself

Abstract

In this paper, our main objective was to predict survival outcomes using DCE-MRI biomarkers in patients with advanced hepatocellular carcinoma (HCC) after progression from 1st-line sorafenib treatment in two prospective phase II trials. This study included 74 participants (men/women = 64/10, mean age 60 ± 11.8 years) with advanced HCC who received 2nd-line targeted therapy (

Indexed as

axitinibhepatocellular carcinomalenalidomidemagnetic resonance imagingsurvival

Identifiers

PMID34638446
PMCPMC8508238
OpenAlexW3203493505

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.